New Analyst Forecast: $CRWD Given 'Market Perform' Rating

Recent analyst ratings for $CRWD are predominantly positive, with 14 buy ratings and a median price target of $425.00; Cantor Fitzgerald and Barclays have set targets as high as $475 and $500, respectively. Congressional members have increased their holdings, with 6 purchases versus 2 sales in the last six months, while company insiders have sold 189 times during the same period. Institutional investors increased their positions, with Morgan Stanley and JP Morgan Chase adding the most shares in Q1 2025.

Analysis

CrowdStrike ($CRWD) presents a dichotomous investment picture based on recent data. On one hand, Wall Street sentiment is overwhelmingly positive, with 14 firms issuing buy ratings and zero sell ratings in recent months. The median analyst price target sits at $425.00, supported by recent high targets such as $475.00 from Cantor Fitzgerald and $500.00 from Barclays. This bullish stance is reinforced by significant institutional accumulation in Q1 2025, with major players like Morgan Stanley increasing its holdings by 1,509,857 shares (+21.2%) and JPMorgan Chase adding 1,388,112 shares (+50.8%). Furthermore, Congressional trading activity shows a net positive bias with 6 purchases against 2 sales in the past six months. Conversely, a starkly contrasting signal emerges from insider activity: there have been 189 sales and zero purchases by $CRWD insiders over the last six months, including substantial disposals by key executives such as CEO George Kurtz (96,076 shares for ~$39.4M) and CFO Burt W. Podbere (40,746 shares for ~$15.8M). This heavy insider selling likely contributes to the stock's overall moderately negative sentiment score of -0.3, despite the positive external indicators. Bernstein's recent 'Market Perform' rating also offers a more measured perspective compared to the widely bullish analyst consensus.

Key Decisions for Investors

• Investors should acknowledge the strong external validation for $CRWD from analysts and institutional accumulation, suggesting potential for further price appreciation towards the median target of $425 and higher individual targets.
• The significant and consistent insider selling by top executives, totaling 189 sales with no purchases in the last six months, warrants careful consideration as it may signal concerns about valuation or future growth not reflected in public consensus.
• It is prudent for investors to closely monitor future insider transaction patterns, upcoming earnings releases, and any changes in institutional holdings for indications that could resolve the current divergence between bullish external sentiment and bearish insider actions.